La'ulu Sonia L, Turner Devon R, Zupan Emily, Genzen Jonathan R
ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah.
ARUP Laboratories, Salt Lake City, Utah.
Lab Med. 2021 Sep 1;52(5):469-476. doi: 10.1093/labmed/lmaa115.
Viscous body fluids present challenges during clinical laboratory testing. The present study was conducted to evaluate the effectiveness of hyaluronidase (HYAL) and ultracentrifugation (UC) pretreatment for a variety of body fluids before clinical chemistry testing.
The following body fluids were evaluated: biliary/hepatic, cerebrospinal, dialysate, drain, pancreatic, pericardial, peritoneal/ascites, pleural, synovial, and vitreous. Analytes assessed included amylase, total bilirubin, cancer antigen 19-9, carcinoembryonic antigen, cholesterol, chloride, creatinine, glucose, lactate dehydrogenase, lipase, potassium, rheumatoid factor, sodium, total protein, triglycerides, urea nitrogen, and uric acid.
Observed percentage differences between HYAL treated and untreated fluids were less than ±15% for all analytes investigated, with a small number showing statistical significance (P <.05). In addition, UC showed increased variability for limited body fluid/analyte combinations.
The HYAL treatment effectively reduced viscosity for body fluids. Validation of specimen pretreatment processes ensures acceptable analytical performance and the absence of unanticipated interferences.
粘性体液在临床实验室检测过程中存在挑战。本研究旨在评估透明质酸酶(HYAL)和超速离心(UC)预处理对多种体液进行临床化学检测前的有效性。
评估了以下几种体液:胆汁/肝脏、脑脊液、透析液、引流液、胰腺、心包、腹膜/腹水、胸膜、滑膜和玻璃体。评估的分析物包括淀粉酶、总胆红素、癌抗原19-9、癌胚抗原、胆固醇、氯、肌酐、葡萄糖、乳酸脱氢酶、脂肪酶、钾、类风湿因子、钠、总蛋白、甘油三酯、尿素氮和尿酸。
对于所有研究的分析物,经HYAL处理和未处理的体液之间观察到的百分比差异小于±15%,少数具有统计学意义(P<.05)。此外,UC显示有限的体液/分析物组合变异性增加。
HYAL处理有效地降低了体液的粘度。标本预处理过程的验证确保了可接受的分析性能和不存在意外干扰。